Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.520
-0.070 (-4.40%)
Feb 12, 2026, 4:00 PM EST - Market closed
Caribou Biosciences Employees
Caribou Biosciences had 147 employees as of December 31, 2024. The number of employees decreased by 11 or -6.96% compared to the previous year.
Employees
147
Change (1Y)
-11
Growth (1Y)
-6.96%
Revenue / Employee
$63,231
Profits / Employee
-$1,068,891
Market Cap
142.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 147 | -11 | -6.96% |
| Dec 31, 2023 | 158 | 21 | 15.33% |
| Dec 31, 2022 | 137 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| ProQR Therapeutics | 166 |
| Cibus | 159 |
| Adagene | 138 |
| Nkarta | 105 |
| Tenaya Therapeutics | 97 |
| Connect Biopharma Holdings | 62 |
CRBU News
- 10 hours ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 8 days ago - Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® - GlobeNewsWire
- 2 months ago - Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 - GlobeNewsWire
- 3 months ago - Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
- 3 months ago - Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - GlobeNewsWire
- 3 months ago - Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - GlobeNewsWire